|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
MondayNovartis oral multiple sclerosis development compound Gilenya®* (FTY720) granted US priority review status![]()
(Posted by Desinie Smith)
Novartis International AG/ Novartis oral multiple sclerosis development compound Gilenya (FTY720) granted US priority review status processed and transmitted by Hugin AS. The isuer is solely responsible for the content of this announcement.
* US Food and Drug Administration grants priority review status after accepting US regulatory for 0.5 mg once-daily Gilenya ( fingolimod)
To read the rest of the article on pr-inside.com click here.
|